ATE474591T1 - Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung - Google Patents

Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung

Info

Publication number
ATE474591T1
ATE474591T1 AT04812757T AT04812757T ATE474591T1 AT E474591 T1 ATE474591 T1 AT E474591T1 AT 04812757 T AT04812757 T AT 04812757T AT 04812757 T AT04812757 T AT 04812757T AT E474591 T1 ATE474591 T1 AT E474591T1
Authority
AT
Austria
Prior art keywords
methods
pharmaceutical compositions
insulin treatment
insulin
treatment
Prior art date
Application number
AT04812757T
Other languages
English (en)
Inventor
Robert Gyurik
Carl Reppucci
Original Assignee
Cpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cpex Pharmaceuticals Inc filed Critical Cpex Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE474591T1 publication Critical patent/ATE474591T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04812757T 2003-12-08 2004-12-02 Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung ATE474591T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52772803P 2003-12-08 2003-12-08
PCT/US2004/040313 WO2005056038A1 (en) 2003-12-08 2004-12-02 Pharmaceutical compositions and methods for insulin treatment

Publications (1)

Publication Number Publication Date
ATE474591T1 true ATE474591T1 (de) 2010-08-15

Family

ID=34676771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812757T ATE474591T1 (de) 2003-12-08 2004-12-02 Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung

Country Status (18)

Country Link
US (4) US7112561B2 (de)
EP (2) EP2241326A1 (de)
JP (2) JP2007513199A (de)
KR (1) KR100978717B1 (de)
CN (2) CN101829319A (de)
AT (1) ATE474591T1 (de)
AU (2) AU2004296784B2 (de)
BR (1) BRPI0418589A (de)
CA (1) CA2547990C (de)
DE (1) DE602004028284D1 (de)
DK (1) DK1706128T3 (de)
EA (1) EA010885B1 (de)
ES (1) ES2348303T3 (de)
IL (1) IL176015A (de)
NO (1) NO330737B1 (de)
NZ (2) NZ547587A (de)
WO (1) WO2005056038A1 (de)
ZA (1) ZA200604683B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1431919A (zh) * 2000-04-03 2003-07-23 巴特勒记忆研究所 装置和制剂
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
CN101829319A (zh) * 2003-12-08 2010-09-15 Cpex药品公司 用于胰岛素治疗的药用组合物及方法
US20060286510A1 (en) * 2005-06-15 2006-12-21 Boghosian Alan A Method of preparing dentition for the taking of a dental impression
US10835351B2 (en) 2005-06-15 2020-11-17 Alan Ara BOGHOSIAN Method of preparing dentition for the taking of a dental impression
US10231805B2 (en) 2005-06-15 2019-03-19 Alan Ara BOGHOSIAN Method of preparing dentition for the taking of a dental impression
WO2007056068A2 (en) * 2005-11-02 2007-05-18 Bentley Pharmaceuticals, Inc. Macrocyclic formulations for transmembrane drug delivery
CN101495132A (zh) * 2006-06-08 2009-07-29 Cpex药品公司 胰岛素组合物
US20080107735A1 (en) * 2006-11-02 2008-05-08 Gyurik Robert J Macrocyclic formulations for transmembrane drug delivery
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2282725A4 (de) * 2008-06-05 2012-07-04 Cpex Pharmaceuticals Inc Nasalformulierungen von insulin
BRPI0923557A2 (pt) 2008-12-22 2016-01-26 Allergan Inc administração de desmopressina intranasal
US20100160214A1 (en) * 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
ES2929471T3 (es) 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Administración segura de desmopresina
US20110097363A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically Effective Preparations of Insulin
EP4070801A1 (de) 2011-03-01 2022-10-12 Nutrition 21, LLC Zusammensetzungen aus insulin und chrom zur behandlung und vorbeugung von diabetes, hypoglykämie und verwandten erkrankungen
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
AU2014293140A1 (en) 2013-07-23 2016-03-03 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
EP3220942B1 (de) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Zusammensetzungen mit niedriger dose desmopressin in kombination mit einem alpha-adrenorezeptor-antagonisten
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211766A (en) 1972-07-10 1980-07-08 Ab Bonnierforetagen Cancer associated polypeptide antigen compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB2002795B (en) 1977-07-15 1982-03-17 Mallinckrodt Inc Nail enamel compositions their preparation and use
US5132459A (en) 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
ATE10272T1 (de) 1979-08-22 1984-11-15 Sandoz Ag Propenylamine, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre verwendung als arzneimittel.
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
ATE14226T1 (de) 1981-12-24 1985-07-15 Ciba Geigy Ag Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
US4760096A (en) 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation
JPH01501143A (ja) 1985-11-04 1989-04-20 ダ−マトロジカル・プロダクツ・オブ・テキサス 爪への薬物の施用のための皮膜形成性製剤用ヴェヒクル、これらのヴェヒクルを基にした薬剤組成物および同じものの使用法
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
WO1987003473A1 (en) * 1985-12-04 1987-06-18 Dean Hsieh Transdermal delivery of drugs
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
CA1291036C (en) 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US4782059A (en) 1986-09-29 1988-11-01 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
US4894375A (en) 1986-09-29 1990-01-16 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
HU200914B (en) 1987-03-09 1990-09-28 Horvath Gyoengyi Lengyelne Process for producing new medical dosage unit suitable for local treatment of fungus infection of nails
US5641475A (en) 1987-05-15 1997-06-24 Tristrata, Inc. Antiodor, antimicrobial and preservative compositions and methods of using same
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
LU86924A1 (fr) 1987-06-19 1989-03-08 Oreal Vernis a ongles anhydres
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US5028431A (en) 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
ATE70446T1 (de) 1988-01-13 1992-01-15 Sanol Arznei Schwarz Gmbh Konzentrierte corticosteroide enthaltende loesungen und verfahren zu deren herstellung.
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4920109A (en) 1988-04-18 1990-04-24 Merck & Co., Inc. Antifungal compositions and method of controlling mycotic infections
US4920112A (en) 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US5160737A (en) 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
US5116603A (en) 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
HUT58201A (en) 1989-03-03 1992-02-28 Sandoz Ag Process for producing antiphlogistic pharmaceutical composition containing naphtalene-methan-amino derivatives
FR2646603B1 (fr) 1989-05-03 1991-07-12 Oreal Composition nettoyante
CA2020888A1 (en) 1989-07-27 1991-01-28 Philippe Guerry Substituted aminoalkoxybenzene derivatives
US5214046A (en) 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
US5562608A (en) 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
EP0472858B2 (de) 1990-07-04 2000-03-15 Kao Corporation Haarbehandlungszusammensetzung
JPH078806B2 (ja) 1990-08-16 1995-02-01 旭化成工業株式会社 カルシトニン類含有経鼻投与用乳剤
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
IT1247138B (it) 1991-03-06 1994-12-12 Dompe Farmaceutici Spa Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico.
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5437272A (en) 1991-05-01 1995-08-01 Alliance Pharmaceutical Corp. Perfluorocarbon associated gas exchange
EP0583358B1 (de) 1991-05-03 1998-12-02 Alliance Pharmaceutical Corporation Partielle Flüssigkeitsbeatmung mittels Fluorkohlenwasserstoffen
HU223343B1 (hu) 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US6005001A (en) 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU219480B (hu) 1991-05-23 2001-04-28 Novartis Ag. Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
TW246682B (de) 1991-08-12 1995-05-01 Procter & Gamble
JPH07503629A (ja) 1991-11-14 1995-04-20 アライアンス　ファーマシューティカル　コーポレイション フルオロカーボンを用いた部分的液体呼吸法および装置
DE4242919A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
IT1261776B (it) 1993-03-12 1996-06-03 Mendes Srl Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5661170A (en) 1994-03-21 1997-08-26 Woodward Laboratories, Inc. Antimicrobial compositions and methods for using the same
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
FR2722102B1 (fr) 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
EP0793517B1 (de) * 1994-11-17 1999-09-08 Alza Corporation Vorrichtung zur erhöhung der wirkstoffsverabreichung durch elektrotransport
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5945409A (en) 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
GB9509631D0 (en) 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
GB9513750D0 (en) 1995-07-06 1995-09-06 Sandoz Ltd Use of allylamines
FR2737118B1 (fr) 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
EP0866683A4 (de) 1995-09-14 1999-01-07 Sorenson Pharmaceutical Inc Mittel und verfahren zur behandlung erkrankter nägel
NZ280065A (en) 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
JP3263598B2 (ja) 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
KR100213465B1 (ko) 1996-11-01 1999-08-02 최좌진 케토프로펜 패취 조성물
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5925616A (en) 1996-08-09 1999-07-20 Buckman Laboratories International, Inc. Treatment of fungal infections using a combination of an anti-fungal compound and an H-alkyl heterocyclic compound
US5993787A (en) 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
JP2002516619A (ja) 1996-10-18 2002-06-04 ユニオン キャンプ コーポレイション エステル末端ポリアミドゲル
US6694975B2 (en) 1996-11-21 2004-02-24 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US5813416A (en) 1997-04-03 1998-09-29 Rudolph; James M. File with sanitizing agent
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
US5976547A (en) 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US6482839B1 (en) 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6267979B1 (en) 1997-08-26 2001-07-31 Wake Forest University Chelators in combination with biocides: treatment of microbially induced biofilm and corrosion
WO1999009997A1 (en) 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6596267B1 (en) 1997-08-27 2003-07-22 California Institute Of Technology Methods and compositions to prevent formation of adhesions in biological tissues
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
KR100883149B1 (ko) 1997-10-22 2009-02-10 젠스 포니카우 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
EP0983037B1 (de) 1998-02-09 2003-05-02 MacroChem Corporation Antimykotischer nagellack
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
US6225075B1 (en) 1998-03-13 2001-05-01 Advanced Research And Technology Institute, Inc. DNA encoding sterol methyltransferase
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
NL1008795C2 (nl) 1998-04-02 1999-10-05 Rene Werenfridus Lodewijk Vroo Samenstelling voor het behandelen van hoeven en werkwijze voor het vervaardigen van de samenstelling.
AU747407B2 (en) 1998-04-14 2002-05-16 Bioagency Ag Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
AU3055099A (en) 1998-05-20 1999-12-06 Charna Chemicals Ltd. A pharmaceutical formulation for nasal administration
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6071541A (en) 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
US6117119A (en) 1998-08-28 2000-09-12 Silipos, Inc. Gelatinous body protection article having a therapeutic additive
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6849263B2 (en) 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CN1355699A (zh) 1999-04-16 2002-06-26 藤泽药品工业株式会社 抗真菌组合物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6485706B1 (en) 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US6403063B1 (en) 1999-07-26 2002-06-11 Kenneth I. Sawyer Method of treating nail fungus
WO2001013956A2 (en) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
JP2003509142A (ja) 1999-09-15 2003-03-11 アラダイム コーポレーション 減圧エアロゾル化孔構造
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
DE10011081A1 (de) 2000-03-09 2001-09-13 Aventis Pharma Gmbh Antiinfektive Wirkstoffkombinationen und ihre Verwendung zur topischen Behandlung von Pilzerkrankungen der Fuß- und Fingernägel
US6281239B1 (en) 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
CN1211164C (zh) 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
US6914051B1 (en) 2000-06-28 2005-07-05 David M Allen Penetrating antibiotic gel for soft tissue diseases
US6503953B2 (en) 2000-07-26 2003-01-07 Atopic Pty Ltd. Methods for treating atopic disorders
WO2002015880A2 (en) 2000-08-25 2002-02-28 Merck Patent Gmbh Powdered mannitol and mannitol-containing compositions
US20050032683A1 (en) 2000-10-04 2005-02-10 Amento Edward P. Methods of modulating apoptosis by administration of relaxin agonists or antagonists
EP1201738A1 (de) 2000-10-30 2002-05-02 Pfw Aroma Chemicals B.V. Parfümzusammensetzung die Cyclohexadecanone enthalten
NZ548358A (en) 2001-02-09 2008-04-30 Genentech Inc Method of identifying agonists of insulin-like growth factor-1
ITMI20010430A1 (it) 2001-03-02 2002-09-02 Dinamite Dipharma S P A In For Metodo per la sintesi di terbinafina
US6878365B2 (en) 2001-03-10 2005-04-12 James Edward Brehove Topical application for treating toenail fungus
US6956058B2 (en) * 2001-04-26 2005-10-18 Kao Corporation Method for improving insulin resistance
CA2451839C (en) 2001-06-22 2013-08-06 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions comprising peptides and permeation enhancers
US6602496B2 (en) 2001-07-05 2003-08-05 Closure Medical Corporation Adhesive treatment for tinea corporis
US6585967B2 (en) 2001-07-05 2003-07-01 Closure Medical Corporation Adhesive treatment for tinea cruris
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
CA2468539C (en) 2001-10-22 2013-01-08 Michael A. Repka Delivery of medicaments to the nail
US6544950B1 (en) 2001-12-06 2003-04-08 University Of Kentucky Research Foundation Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury
US20030211995A1 (en) 2001-12-21 2003-11-13 Kokai-Kun John Fitzgerald Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
KR100459275B1 (ko) 2001-12-28 2004-12-03 주식회사유한양행 터비나핀 또는 그의 염산염의 제조방법
US6899890B2 (en) 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US6958142B2 (en) 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
WO2004064757A2 (en) 2003-01-23 2004-08-05 Shire Laboratories, Inc. Absorption enhancing agents
EP1668358B1 (de) 2003-08-05 2014-12-10 The Research Foundation of State University of New York Rekonstitutionsmedium für protein- und peptidformulierungen
CN101829319A (zh) * 2003-12-08 2010-09-15 Cpex药品公司 用于胰岛素治疗的药用组合物及方法

Also Published As

Publication number Publication date
EP1706128A1 (de) 2006-10-04
AU2010219399A1 (en) 2010-09-30
EA010885B1 (ru) 2008-12-30
NZ547587A (en) 2009-09-25
EA200601123A1 (ru) 2006-10-27
IL176015A (en) 2010-12-30
CA2547990A1 (en) 2005-06-23
CN1913912B (zh) 2010-06-16
US8044020B2 (en) 2011-10-25
US20100144593A1 (en) 2010-06-10
NO330737B1 (no) 2011-06-27
BRPI0418589A (pt) 2008-01-29
WO2005056038A1 (en) 2005-06-23
US7651996B2 (en) 2010-01-26
US20050123592A1 (en) 2005-06-09
EP2241326A1 (de) 2010-10-20
KR100978717B1 (ko) 2010-08-30
DK1706128T3 (da) 2010-10-04
JP2009292820A (ja) 2009-12-17
CN101829319A (zh) 2010-09-15
EP1706128B1 (de) 2010-07-21
AU2004296784B2 (en) 2010-12-02
US7112561B2 (en) 2006-09-26
CN1913912A (zh) 2007-02-14
NO20063135L (no) 2006-09-08
NZ578735A (en) 2011-06-30
IL176015A0 (en) 2006-10-05
KR20060117989A (ko) 2006-11-17
DE602004028284D1 (de) 2010-09-02
ES2348303T3 (es) 2010-12-02
ZA200604683B (en) 2007-04-25
HK1097464A1 (en) 2007-06-29
US20070010425A1 (en) 2007-01-11
JP2007513199A (ja) 2007-05-24
US20090156464A1 (en) 2009-06-18
AU2004296784A1 (en) 2005-06-23
EP1706128A4 (de) 2008-11-26
CA2547990C (en) 2011-08-02

Similar Documents

Publication Publication Date Title
ATE474591T1 (de) Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
CY1119029T1 (el) Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
NO20045056L (no) Fremgangsmater for behandling av hepatitt
EP1990059A3 (de) Verfahren zur Behandlung von Krebs
TW200738270A (en) Method of treating depression using a TNFα antibody
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
UA85041C2 (ru) Способ лечения кишечной непроходимости
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
IL220043A0 (en) Methods for producing ??-galactosidase a compositions
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
WO2006096173A8 (en) Pharmaceutical compositions and methods for peptide treatment
CY1110538T1 (el) S-μιρταζαπινη για τη θεραπεια των εξαψεων
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
BR0302037B1 (pt) método e aparelho de tratamento de costura.
NO20054631D0 (no) Antistoff mot tumorspesifikt antigen som mal
ATE411298T1 (de) Antibakterielle und/oder gegen protozoen wirksame nitroimidazolderivatverbindungen mit ureasehemmender wirkung, verfahren zur herstellung dieser verbindungen und deren verwendung in pharmazeutischen zusammensetzungen und medikamenten
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
RU2003102451A (ru) Способ лечения сифилитического васкулита
DE10342747A1 (de) Pharmazeutischer Wirkstoff gegen Melanome
DE60016194D1 (de) Radioaktives cisplatin zur krebsbehandlung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties